U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C21H28O2
Molecular Weight 312.4458
Optical Activity ( - )
Defined Stereocenters 6 / 6
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of LEVONORGESTREL

SMILES

[H][C@@]12CC[C@@](O)(C#C)[C@@]1(CC)CC[C@]3([H])[C@@]4([H])CCC(=O)C=C4CC[C@@]23[H]

InChI

InChIKey=WWYNJERNGUHSAO-XUDSTZEESA-N
InChI=1S/C21H28O2/c1-3-20-11-9-17-16-8-6-15(22)13-14(16)5-7-18(17)19(20)10-12-21(20,23)4-2/h2,13,16-19,23H,3,5-12H2,1H3/t16-,17+,18+,19-,20-,21-/m0/s1

HIDE SMILES / InChI
Molecular Formula C21H28O2
Molecular Weight 312.4458
Charge 0
Count
Stereochemistry ABSOLUTE
Additional Stereochemistry No
Defined Stereocenters 6 / 6
E/Z Centers 0
Optical Activity UNSPECIFIED

Description
Curator's Comment: description was created based on several sources, including https://www.ncbi.nlm.nih.gov/pubmed/25698840

Norgestrel is synthetic steroidal progestin that is used in combination with ethinyl estradiol for oral contraception. Norgestrel is composed of a racemic mixture of two stereoisomers, dextronorgestrel and levonorgestrel. However, only the levorotary enantiomer (levonorgestrel) is biologically active. Norgestrel (and more specifically the active stereoisomer levonorgestrel) binds to the progesterone and estrogen receptors within the female reproductive tract, the mammary gland, the hypothalamus, and the pituitary. Once bound to the receptor, progestins like levonorgestrel will slow the frequency of release of gonadotropin releasing hormone (GnRH) from the hypothalamus and blunt the pre-ovulatory LH (luteinizing hormone) surge. Loss of the LH surge inhibits ovulation and thereby prevents pregnancy. Norgestrel in combination with ethinyl estradiol is indicated for the prevention of pregnancy in women who elect to use this product as a method of contraception.

Originator

Approval Year

1968
48
Targets

Targets

Primary TargetPharmacologyConditionPotency
Binding Agent
1037
Agonist
2637
Binding Agent
1037
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Preventing
Approved
8307
MIRENA

Approved Use

Mirena is indicated for intrauterine contraception for up to 5 years. Mirena is also indicated for the treatment of heavy menstrual bleeding in women who choose to use intrauterine contraception as their method of contraception. Mirena is recommended for women who have had at least one child. The system should be replaced after 5 years if continued use is desired.

Launch Date

9.7606081E11
Primary
Approved
8307
MIRENA

Approved Use

Mirena is indicated for intrauterine contraception for up to 5 years. Mirena is also indicated for the treatment of heavy menstrual bleeding in women who choose to use intrauterine contraception as their method of contraception. Mirena is recommended for women who have had at least one child. The system should be replaced after 5 years if continued use is desired.

Launch Date

9.7606081E11
Preventing
Approved
8307
OVRETTE

Approved Use

Progestin-only oral contraceptives are indicated for the prevention of pregnancy.

Launch Date

1.20182399E11
Preventing
Approved
8307
ELINEST

Approved Use

Oral contraceptives are indicated for the prevention of pregnancy in women who elect to use oral contraceptives as a method of contraception.

Launch Date

1.33289279E12
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
16.2 ng/mL
EXPERIMENT
https://www.ncbi.nlm.nih.gov/pubmed/30703352
1.5 mg single, oral
dose: 1.5 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
LEVONORGESTREL blood
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE
food status: FASTED
14.11 ng/mL
EXPERIMENT
https://www.ncbi.nlm.nih.gov/pubmed/12169384
0.75 mg single, oral
dose: 0.75 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
LEVONORGESTREL plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE
food status: FASTED
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
360.1 ng × h/mL
EXPERIMENT
https://www.ncbi.nlm.nih.gov/pubmed/30703352
1.5 mg single, oral
dose: 1.5 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
LEVONORGESTREL blood
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE
food status: FASTED
123.1 ng × h/mL
EXPERIMENT
https://www.ncbi.nlm.nih.gov/pubmed/12169384
0.75 mg single, oral
dose: 0.75 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
LEVONORGESTREL plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE
food status: FASTED
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
29.7 h
EXPERIMENT
https://www.ncbi.nlm.nih.gov/pubmed/30703352
1.5 mg single, oral
dose: 1.5 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
LEVONORGESTREL blood
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE
food status: FASTED
24.4 h
EXPERIMENT
https://www.ncbi.nlm.nih.gov/pubmed/12169384
0.75 mg single, oral
dose: 0.75 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
LEVONORGESTREL plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE
food status: FASTED
Doses

Doses

DosePopulationAdverse events​
20 ug 1 times / day multiple, intrauterine
Recommended
Dose: 20 ug, 1 times / day
Route: intrauterine
Route: multiple
Dose: 20 ug, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/25934164
Page: p.10
healthy, 16-45
n = 1714
Health Status: healthy
Condition: Prevention of pregnancy
Age Group: 16-45
Sex: F
Population Size: 1714
Sources:
https://pubmed.ncbi.nlm.nih.gov/25934164
Page: p.10
Disc. AE: Bleeding...
AEs leading to
discontinuation/dose reduction:
Bleeding (1.5%)
Sources:
https://pubmed.ncbi.nlm.nih.gov/25934164
Page: p.10
20 ug 1 times / day multiple, intrauterine
Recommended
Dose: 20 ug, 1 times / day
Route: intrauterine
Route: multiple
Dose: 20 ug, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/29560743
Page: p.2
healthy, 27.3 ± 5.7
n = 1700
Health Status: healthy
Condition: Prevention of pregnancy
Age Group: 27.3 ± 5.7
Sex: F
Population Size: 1700
Sources:
https://pubmed.ncbi.nlm.nih.gov/29560743
Page: p.2
Disc. AE: Menstrual irregularity, Amenorrhea...
AEs leading to
discontinuation/dose reduction:
Menstrual irregularity (0.7%)
Amenorrhea (0.06%)
Sources:
https://pubmed.ncbi.nlm.nih.gov/29560743
Page: p.2
90 ug 1 times / day multiple, oral
Recommended
Dose: 90 ug, 1 times / day
Route: oral
Route: multiple
Dose: 90 ug, 1 times / day
Co-administed with::
ethinyl estradiol, p.o(20 ug; q.d; 1 year)
Sources:
https://pubmed.ncbi.nlm.nih.gov/19913143
Page: p.507
healthy, 27.6±6.7
n = 323
Health Status: healthy
Condition: Prevention of pregnancy
Age Group: 27.6±6.7
Sex: F
Population Size: 323
Sources:
https://pubmed.ncbi.nlm.nih.gov/19913143
Page: p.507
Disc. AE: Metrorrhagia, Bleeding vaginal...
AEs leading to
discontinuation/dose reduction:
Metrorrhagia (8.7%)
Bleeding vaginal (3.7%)
Sources:
https://pubmed.ncbi.nlm.nih.gov/19913143
Page: p.507
AEs

AEs

AESignificanceDosePopulation
Bleeding 1.5%
Disc. AE
20 ug 1 times / day multiple, intrauterine
Recommended
Dose: 20 ug, 1 times / day
Route: intrauterine
Route: multiple
Dose: 20 ug, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/25934164
Page: p.10
healthy, 16-45
n = 1714
Health Status: healthy
Condition: Prevention of pregnancy
Age Group: 16-45
Sex: F
Population Size: 1714
Sources:
https://pubmed.ncbi.nlm.nih.gov/25934164
Page: p.10
Amenorrhea 0.06%
Disc. AE
20 ug 1 times / day multiple, intrauterine
Recommended
Dose: 20 ug, 1 times / day
Route: intrauterine
Route: multiple
Dose: 20 ug, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/29560743
Page: p.2
healthy, 27.3 ± 5.7
n = 1700
Health Status: healthy
Condition: Prevention of pregnancy
Age Group: 27.3 ± 5.7
Sex: F
Population Size: 1700
Sources:
https://pubmed.ncbi.nlm.nih.gov/29560743
Page: p.2
Menstrual irregularity 0.7%
Disc. AE
20 ug 1 times / day multiple, intrauterine
Recommended
Dose: 20 ug, 1 times / day
Route: intrauterine
Route: multiple
Dose: 20 ug, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/29560743
Page: p.2
healthy, 27.3 ± 5.7
n = 1700
Health Status: healthy
Condition: Prevention of pregnancy
Age Group: 27.3 ± 5.7
Sex: F
Population Size: 1700
Sources:
https://pubmed.ncbi.nlm.nih.gov/29560743
Page: p.2
Bleeding vaginal 3.7%
Disc. AE
90 ug 1 times / day multiple, oral
Recommended
Dose: 90 ug, 1 times / day
Route: oral
Route: multiple
Dose: 90 ug, 1 times / day
Co-administed with::
ethinyl estradiol, p.o(20 ug; q.d; 1 year)
Sources:
https://pubmed.ncbi.nlm.nih.gov/19913143
Page: p.507
healthy, 27.6±6.7
n = 323
Health Status: healthy
Condition: Prevention of pregnancy
Age Group: 27.6±6.7
Sex: F
Population Size: 323
Sources:
https://pubmed.ncbi.nlm.nih.gov/19913143
Page: p.507
Metrorrhagia 8.7%
Disc. AE
90 ug 1 times / day multiple, oral
Recommended
Dose: 90 ug, 1 times / day
Route: oral
Route: multiple
Dose: 90 ug, 1 times / day
Co-administed with::
ethinyl estradiol, p.o(20 ug; q.d; 1 year)
Sources:
https://pubmed.ncbi.nlm.nih.gov/19913143
Page: p.507
healthy, 27.6±6.7
n = 323
Health Status: healthy
Condition: Prevention of pregnancy
Age Group: 27.6±6.7
Sex: F
Population Size: 323
Sources:
https://pubmed.ncbi.nlm.nih.gov/19913143
Page: p.507
Overview

Overview

CYP3A4CYP2C9CYP2D6hERG
substrate
1670

inhibitor
1532
substrate
985

inhibitor
1695
inhibitor
1789

OverviewOther

Other InhibitorOther SubstrateOther Inducer
CYP1A2
1463

CYP2A6
670

CYP2C19
1410

CYP2E1
846

CYP2C8
869

CYP2B6
770

BSEP
392

MRP2
363

MRP3
156

MRP4
202
CYP1A2
1013

CYP2A6
510

CYP2C19
955

CYP2E1
633
Drug as perpetrator​

Drug as perpetrator​

TargetModalityActivityMetaboliteClinical evidence
OATP1B3
700
 likely
BSEP
393
 no [IC50 >133 uM]
MRP2
452
 no [IC50 >133 uM]
MRP3
206
 no [IC50 >133 uM]
MRP4
235
 no [IC50 >133 uM]
CYP1A2
1620
 no [IC50 >250 uM]
CYP2A6
702
 no [IC50 >250 uM]
CYP2C19
1484
 no [IC50 >250 uM]
CYP2C9
1747
 no [IC50 >250 uM]
CYP2D6
1826
 no [IC50 >250 uM]
CYP2E1
929
 no [IC50 >250 uM]
CYP3A4
1857
 yes [IC50 13.6 uM]
CYP2B6
946
 yes
CYP2C8
923
 yes
Drug as victim

Drug as victim

TargetModalityActivityMetaboliteClinical evidence
CYP2A6
510
 likely
CYP2C9
985
 likely
CYP2E1
633
 likely
CYP3A4
1670
 major
yes (co-administration study)
Comment: Concomitant administration of efavirenz (moderate CYP3A inducer) has been found to reduce plasma levels of levonorgestrel (AUC) by around 50%.
Page: (ClinPharm) 16-17
CYP2C19
955
 minor
CYP1A2
1013
 unlikely
Sourcing

Sourcing

Vendor/AggregatorIDURL
ChEBI
CHEBI:6443
https://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI:6443
ChemicalBook
CB2752440
https://www.chemicalbook.com/ChemicalProductProperty_EN_CB2752440
ChemicalBook
CB7125746
https://www.chemicalbook.com/ChemicalProductProperty_EN_CB7125746
MolPort
MolPort-002-510-453
https://www.molport.com/shop/molecule-link/MolPort-002-510-453
Selleck Chemicals
Levonorgestrel(Levonelle)
http://www.selleckchem.com/products/Levonorgestrel(Levonelle).html
ZINC
ZINC000003814395
http://zinc15.docking.org/substances/ZINC000003814395
eMolecules
29781161
https://www.emolecules.com/cgi-bin/more?vid=29781161
eMolecules
494705
https://www.emolecules.com/cgi-bin/more?vid=494705
PubMed

PubMed

TitleDatePubMed
Nomenclature of the gonane progestins.
1999 Dec
A lower dosage levonorgestrel and testosterone combination effectively suppresses spermatogenesis and circulating gonadotropin levels with fewer metabolic effects than higher dosage combinations.
1999 May-Jun
Induction of estrogen receptor-alpha and -beta activities by synthetic progestins.
2000 Apr
Non-protein bound dienogest in serum and salivary dienogest in women taking the oral contraceptives Certostat and Valette.
2001 Apr
Oral contraceptives, thrombosis and haemostasis.
2001 Apr
Appeal court bans use of emergency contraceptive in Chile.
2001 Apr 14
Influence of two low-dose oral contraceptives on pulsatile gonadotropin secretion.
2001 Aug
Over-the-counter advice for genital problems: the role of the community pharmacist.
2001 Aug
Treatment of menorrhagia with the levonorgestrel intrauterine system versus endometrial resection.
2001 Aug
The relation of oxidized LDL autoantibodies and long-term hormone replacement therapy to ultrasonographically assessed atherosclerotic plaque quantity and severity in postmenopausal women.
2001 Aug
The levonorgestrel intrauterine system: the benefits of reduced bleeding.
2001 Jan
Sixty thousand woman-years of experience on the levonorgestrel intrauterine system: an epidemiological survey in Finland.
2001 Jan
The levonorgestrel intrauterine system: more than a contraceptive.
2001 Jan
Intrauterine contraception--what now and what next?
2001 Jan
Internet availability of contraceptives.
2001 Jan
Young women requesting emergency contraception are, despite contraceptive counseling, a high risk group for new unintended pregnancies.
2001 Jul
Levonorgestrel-only emergency contraception: real-world tolerance and efficacy.
2001 Jul
Effects of two low-dose oral contraceptives containing ethinylestradiol and either desogestrel or levonorgestrel on serum lipids and lipoproteins with particular regard to LDL size.
2001 Jul
Multicenter, comparative study of cycle control, efficacy and tolerability of two low-dose oral contraceptives containing 20 microg ethinylestradiol/100 microg levonorgestrel and 20 microg ethinylestradiol/500 microg norethisterone.
2001 Jul
A village would be nice but...it takes a long-acting contraceptive to prevent repeat adolescent pregnancies.
2001 Jul
Evaluation of genotoxic potential of synthetic progestins-norethindrone and norgestrel in human lymphocytes in vitro.
2001 Jul 25
Weight change and adverse event incidence with a low-dose oral contraceptive: two randomized, placebo-controlled trials.
2001 Jun
Comparison of a novel norgestimate/ethinyl estradiol oral contraceptive (Ortho Tri-Cyclen Lo) with the oral contraceptive Loestrin Fe 1/20.
2001 Jun
Treatment of menorrhagia with a novel 'frameless' intrauterine levonorgestrel-releasing drug delivery system: a pilot study.
2001 Jun
The effects of two progrestogen-only pills containing either desogestrel (75 microgram/day) or levonorgestrel (30 microgram/day) on carbohydrate metabolism and adrenal and thyroid function.
2001 Jun
The need for more active promotion of emergency contraception.
2001 Jun
Protein S levels are lower in women receiving desogestrel-containing combined oral contraceptives (COCs) than in women receiving levonorgestrel-containing COCs at steady state and on cross-over.
2001 Jun
Treatment of menorrhagia.
2001 Jun 9
Clinical recommendations for oxcarbazepine.
2001 Mar
Mechanism of action of hormonal preparations used for emergency contraception: a review of the literature.
2001 Mar
Preferential prescribing of type of combined oral contraceptive pill by general practitioners to teenagers with acne.
2001 Mar
Practices of prescribing oral contraceptives in Poland.
2001 Mar
New IUD approved.
2001 Mar
Use of a levonorgestrel-releasing intrauterine device in the treatment of rectovaginal endometriosis.
2001 Mar
Increased adhesiveness and internalization of Neisseria gonorrhoeae and changes in the expression of epithelial gonococcal receptors in the Fallopian tube of copper T and Norplant users.
2001 Mar
Constant estrogen, intermittent progestogen vs. continuous combined hormone replacement therapy: tolerability and effect on vasomotor symptoms.
2001 Mar
Levonorgestrel-releasing intrauterine devices.
2001 Mar 10
Determination of steroid sex hormones and related synthetic compounds considered as endocrine disrupters in water by fully automated on-line solid-phase extraction-liquid chromatography-diode array detection.
2001 Mar 16
[After levonorgestrel, will mifepristone (RU486) be the next day-after pill?].
2001 Mar 31
Effects of postmenopausal hormone replacement therapy on lipid, lipoprotein, and apolipoprotein (a) concentrations: analysis of studies published from 1974-2000.
2001 May
Effects of natural products and nutraceuticals on steroid hormone-regulated gene expression.
2001 Oct
[Low-dose oral contraception and bone density].
2001 Sep
Levonorgestrel-releasing IUD and breast cancer.
2001 Sep
Endometrial expression of glycodelin in women with levonorgestrel-releasing subdermal implants.
2001 Sep
Patents

Patents

20010005728
17
JP1070410A
6
JP2002338318A
4
JP2002543156A
35
JP2005500299A
34
JP2006096775A
34
JP2007524648A
4
JP2010180236A
4
JPH00673008A
4
JPH0395994A
4
JPH0437741A
4
JPS6168421A
4
JPS6470410A
6

Sample Use Guides

In Vivo Use Guide
Mirena contains 52 mg of levonorgestrel (LNG). Initially, LNG is released at a rate of approximately 20 mcg/day. This rate decreases progressively to half that value after 5 years. Mirena must be removed by the end of the fifth year and can be replaced at the time of removal with a new Mirena if continued contraceptive protection is desired.
Route of Administration: Vaginal
In Vitro Use Guide
5 × 10(-5) mol/L Levonorgestrel (LNG) revealed a time-dependent inhibition of cell proliferation and an increase of apoptosis in both human endometrial stromal cells (HESCs) and glandular cells (HEGCs). Furthermore, these cells demonstrated a significant Gap Junctional Intercellular Communication (GJIC) enhancement upon treatment with 5 × 10(-5) mol/L for 48 hours. The effects of LNG were most noticeable in HESCs rather than in HEGCs.
Substance Class Chemical
Created
by admin
on Fri Dec 16 16:48:28 UTC 2022
Edited
by admin
on Fri Dec 16 16:48:28 UTC 2022
Record UNII
5W7SIA7YZW
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
LEVONORGESTREL
EP   HSDB   INN   JAN   MART.   ORANGE BOOK   USAN   USP   USP-RS   VANDF   WHO-DD   WHO-IP  
INN   USAN  
Official Name English
LEVONORGESTREL COMPONENT OF OPCICON ONE-STEP
Brand Name English
LEVONORGESTREL [USP IMPURITY]
Common Name English
KURVELO COMPONENT LEVONORGESTREL
Brand Name English
AVIANE COMPONENT LEVONORGESTREL
Brand Name English
TRIPHASIL COMPONENT LEVONORGESTREL
Brand Name English
NSC-744007
Code English
LEVONORGESTREL [MART.]
Common Name English
levonorgestrel [INN]
Common Name English
NORGESTREL (-)-FORM [MI]
Common Name English
LEVONORGESTREL COMPONENT OF SETLAKIN
Brand Name English
LEVONORGESTREL [EP MONOGRAPH]
Common Name English
LESSINA COMPONENT LEVONORGESTREL
Brand Name English
LEVONORGESTREL COMPONENT OF INTROVALE
Common Name English
NORDETTE COMPONENT LEVONORGESTREL
Brand Name English
CLIMARA PRO COMPONENT LEVONORGESTREL
Common Name English
LOSEASONIQUE COMPONENT LEVONORGESTREL
Common Name English
ELIFEMME COMPONENT LEVONORGESTREL
Brand Name English
LEVONORGESTREL COMPONENT OF KYLEENA
Brand Name English
LNG
Common Name English
LEVONORGESTREL COMPONENT OF CLIMARA PRO
Common Name English
NORGESTIMATE IMPURITY B [EP IMPURITY]
Common Name English
Levonorgestrel [WHO-DD]
Common Name English
LEVONORGESTREL COMPONENT OF LYBREL
Common Name English
PREVEN COMPONENT LEVONORGESTREL
Common Name English
LEVONORGESTREL COMPONENT OF LOSEASONIQUE
Common Name English
LEVONORGESTREL COMPONENT OF QUASENSE
Common Name English
SEASONIQUE COMPONENT LEVONORGESTREL
Common Name English
LEVONORGESTREL [JAN]
Common Name English
MARLISSA COMPONENT LEVONORGESTREL
Brand Name English
LILETTA
Brand Name English
LEVONORGESTREL [USP-RS]
Common Name English
NORGESTREL (-)-FORM
MI  
Common Name English
WY-5104
Code English
LEVLITE COMPONENT LEVONORGESTREL
Common Name English
ALESSE COMPONENT LEVONORGESTREL
Common Name English
LEVONORGESTREL [ORANGE BOOK]
Common Name English
LEVONORGESTREL COMPONENT OF ALTAVERA
Common Name English
MYZILRA COMPONENT LEVONORGESTREL
Brand Name English
(-)-13-ETHYL-17-HYDROXY-18,19-DINOR-17.ALPHA.-PREGN-4-EN-20-YN-3-ONE
Common Name English
KYLEENA COMPONENT LEVONORGESTREL
Brand Name English
TRIVORA COMPONENT LEVONORGESTREL
Brand Name English
BAY86-5028
Code English
ALTAVERA COMPONENT LEVONORGESTREL
Common Name English
LEVONORGESTREL COMPONENT OF LEVONEST
Common Name English
LYBREL COMPONENT LEVONORGESTREL
Common Name English
VIENVA COMPONENT LEVONORGESTREL
Brand Name English
PLASTIC IUD WITH LEVONORGESTREL
Common Name English
LEVONORGESTREL [WHO-IP]
Common Name English
ENPRESSE COMPONENT LEVONORGESTREL
Brand Name English
SETLAKIN COMPONENT LEVONORGESTREL
Brand Name English
SEASONALE COMPONENT LEVONORGESTREL
Common Name English
LEVONORGESTRELUM [WHO-IP LATIN]
Common Name English
MIRENA
Brand Name English
LEVONORGESTREL [USAN]
Common Name English
LEVONORGESTREL [USP MONOGRAPH]
Common Name English
LEVONORGESTREL COMPONENT OF PREVEN
Common Name English
TWIRLA COMPONENT LEVONORGESTREL
Brand Name English
LEVONORGESTREL COMPONENT OF SEASONIQUE
Common Name English
LEVONORGESTREL COMPONENT OF TWIRLA
Brand Name English
INTROVALE COMPONENT LEVONORGESTREL
Common Name English
QUASENSE COMPONENT LEVONORGESTREL
Common Name English
NORPLANT
Brand Name English
LEVORA COMPONENT LEVONORGESTREL
Brand Name English
LEVONORGESTREL COMPONENT OF ALESSE
Common Name English
LEVONORGESTREL COMPONENT OF LEVLITE
Common Name English
18,19-DINORPREGN-4-EN-20-YN-3-ONE, 13-ETHYL-17-HYDROXY-, (17.ALPHA.)-(-)-
Common Name English
LEVONORGESTREL COMPONENT OF SEASONALE
Common Name English
OPCICON ONE-STEP COMPONENT LEVONORGESTREL
Brand Name English
AFIRMELLE COMPONENT LEVONORGESTREL
Brand Name English
QUARTETTE COMPONENT LEVONORGESTREL
Brand Name English
FALLBACK SOLO
Brand Name English
NORGESTREL, (-)-
Common Name English
ORSYTHIA COMPONENT LEVONORGESTREL
Brand Name English
PORTIA COMPONENT LEVONORGESTREL
Brand Name English
PLAN B
Brand Name English
IMPLANT WITH LEVONORGESTREL
Common Name English
LEVONORGESTREL [HSDB]
Common Name English
LEVONORGESTREL [VANDF]
Common Name English
LEVONEST COMPONENT LEVONORGESTREL
Common Name English
Classification Tree Code System Code
WHO-ATC G03AC03
Created by admin on Fri Dec 16 16:48:28 UTC 2022 , Edited by admin on Fri Dec 16 16:48:28 UTC 2022
WHO-VATC QG03AC03
Created by admin on Fri Dec 16 16:48:29 UTC 2022 , Edited by admin on Fri Dec 16 16:48:29 UTC 2022
NDF-RT N0000011301
Created by admin on Fri Dec 16 16:48:29 UTC 2022 , Edited by admin on Fri Dec 16 16:48:29 UTC 2022
WHO-VATC QG03AA07
Created by admin on Fri Dec 16 16:48:29 UTC 2022 , Edited by admin on Fri Dec 16 16:48:29 UTC 2022
WHO-ESSENTIAL MEDICINES LIST 18.3.1 (ETH/LEV)
Created by admin on Fri Dec 16 16:48:29 UTC 2022 , Edited by admin on Fri Dec 16 16:48:29 UTC 2022
WHO-VATC QG03AB03
Created by admin on Fri Dec 16 16:48:29 UTC 2022 , Edited by admin on Fri Dec 16 16:48:29 UTC 2022
WHO-ATC G03AA07
Created by admin on Fri Dec 16 16:48:28 UTC 2022 , Edited by admin on Fri Dec 16 16:48:28 UTC 2022
WHO-ATC G03AD01
Created by admin on Fri Dec 16 16:48:28 UTC 2022 , Edited by admin on Fri Dec 16 16:48:28 UTC 2022
WHO-ATC G03FB09
Created by admin on Fri Dec 16 16:48:28 UTC 2022 , Edited by admin on Fri Dec 16 16:48:28 UTC 2022
NCI_THESAURUS C776
Created by admin on Fri Dec 16 16:48:29 UTC 2022 , Edited by admin on Fri Dec 16 16:48:29 UTC 2022
NDF-RT N0000175830
Created by admin on Fri Dec 16 16:48:29 UTC 2022 , Edited by admin on Fri Dec 16 16:48:29 UTC 2022
LIVERTOX 555
Created by admin on Fri Dec 16 16:48:28 UTC 2022 , Edited by admin on Fri Dec 16 16:48:28 UTC 2022
WHO-ATC G03FA11
Created by admin on Fri Dec 16 16:48:28 UTC 2022 , Edited by admin on Fri Dec 16 16:48:28 UTC 2022
NDF-RT N0000175602
Created by admin on Fri Dec 16 16:48:29 UTC 2022 , Edited by admin on Fri Dec 16 16:48:29 UTC 2022
NDF-RT N0000175832
Created by admin on Fri Dec 16 16:48:29 UTC 2022 , Edited by admin on Fri Dec 16 16:48:29 UTC 2022
WHO-VATC QG03AD01
Created by admin on Fri Dec 16 16:48:29 UTC 2022 , Edited by admin on Fri Dec 16 16:48:29 UTC 2022
WHO-VATC QG03FB09
Created by admin on Fri Dec 16 16:48:29 UTC 2022 , Edited by admin on Fri Dec 16 16:48:29 UTC 2022
WHO-VATC QG03FA11
Created by admin on Fri Dec 16 16:48:29 UTC 2022 , Edited by admin on Fri Dec 16 16:48:29 UTC 2022
WHO-ESSENTIAL MEDICINES LIST 18.3.1
Created by admin on Fri Dec 16 16:48:29 UTC 2022 , Edited by admin on Fri Dec 16 16:48:29 UTC 2022
WHO-ATC G03AB03
Created by admin on Fri Dec 16 16:48:28 UTC 2022 , Edited by admin on Fri Dec 16 16:48:28 UTC 2022
Code System Code Type Description
EPA CompTox
DTXSID3036496
Created by admin on Fri Dec 16 16:48:28 UTC 2022 , Edited by admin on Fri Dec 16 16:48:28 UTC 2022
PRIMARY
RS_ITEM_NUM
1362602
Created by admin on Fri Dec 16 16:48:29 UTC 2022 , Edited by admin on Fri Dec 16 16:48:29 UTC 2022
PRIMARY
DAILYMED
5W7SIA7YZW
Created by admin on Fri Dec 16 16:48:28 UTC 2022 , Edited by admin on Fri Dec 16 16:48:28 UTC 2022
PRIMARY
LACTMED
Intrauterine Levonorgestrel
Created by admin on Fri Dec 16 16:48:28 UTC 2022 , Edited by admin on Fri Dec 16 16:48:28 UTC 2022
PRIMARY
INN
3475
Created by admin on Fri Dec 16 16:48:28 UTC 2022 , Edited by admin on Fri Dec 16 16:48:28 UTC 2022
PRIMARY
EVMPD
SUB08483MIG
Created by admin on Fri Dec 16 16:48:28 UTC 2022 , Edited by admin on Fri Dec 16 16:48:28 UTC 2022
PRIMARY
PUBCHEM
13109
Created by admin on Fri Dec 16 16:48:29 UTC 2022 , Edited by admin on Fri Dec 16 16:48:29 UTC 2022
PRIMARY
MESH
D016912
Created by admin on Fri Dec 16 16:48:28 UTC 2022 , Edited by admin on Fri Dec 16 16:48:28 UTC 2022
PRIMARY
ECHA (EC/EINECS)
212-349-8
Created by admin on Fri Dec 16 16:48:28 UTC 2022 , Edited by admin on Fri Dec 16 16:48:28 UTC 2022
PRIMARY
NSC
744007
Created by admin on Fri Dec 16 16:48:29 UTC 2022 , Edited by admin on Fri Dec 16 16:48:29 UTC 2022
PRIMARY
LACTMED
Oral Levonorgestrel
Created by admin on Fri Dec 16 16:48:28 UTC 2022 , Edited by admin on Fri Dec 16 16:48:28 UTC 2022
PRIMARY
MERCK INDEX
M8063
Created by admin on Fri Dec 16 16:48:28 UTC 2022 , Edited by admin on Fri Dec 16 16:48:28 UTC 2022
PRIMARY Merck Index
WHO INTERNATIONAL PHARMACOPEIA
LEVONORGESTREL
Created by admin on Fri Dec 16 16:48:29 UTC 2022 , Edited by admin on Fri Dec 16 16:48:29 UTC 2022
PRIMARY Description: A white or almost white, crystalline powder; odourless. Solubility: Practically insoluble in water; slightly soluble in ethanol (~750 g/l) TS and ether R. Category: Contraceptive. Storage: Levonorgestrel should be kept in a well-closed container, protected from light.Definition: Levonorgestrel contains not less than 98.0% and not more than 102.0% of C21H28O2, calculated with reference to the dried substance.
ChEMBL
CHEMBL1389
Created by admin on Fri Dec 16 16:48:28 UTC 2022 , Edited by admin on Fri Dec 16 16:48:28 UTC 2022
PRIMARY
LACTMED
Levonorgestrel Implant
Created by admin on Fri Dec 16 16:48:28 UTC 2022 , Edited by admin on Fri Dec 16 16:48:28 UTC 2022
PRIMARY
FDA UNII
5W7SIA7YZW
Created by admin on Fri Dec 16 16:48:28 UTC 2022 , Edited by admin on Fri Dec 16 16:48:28 UTC 2022
PRIMARY
DRUG CENTRAL
1572
Created by admin on Fri Dec 16 16:48:28 UTC 2022 , Edited by admin on Fri Dec 16 16:48:28 UTC 2022
PRIMARY
DRUG BANK
DB00367
Created by admin on Fri Dec 16 16:48:28 UTC 2022 , Edited by admin on Fri Dec 16 16:48:28 UTC 2022
PRIMARY
CHEBI
6443
Created by admin on Fri Dec 16 16:48:28 UTC 2022 , Edited by admin on Fri Dec 16 16:48:28 UTC 2022
PRIMARY
CAS
797-63-7
Created by admin on Fri Dec 16 16:48:28 UTC 2022 , Edited by admin on Fri Dec 16 16:48:28 UTC 2022
PRIMARY
HSDB
6483
Created by admin on Fri Dec 16 16:48:28 UTC 2022 , Edited by admin on Fri Dec 16 16:48:28 UTC 2022
PRIMARY
RXCUI
6373
Created by admin on Fri Dec 16 16:48:29 UTC 2022 , Edited by admin on Fri Dec 16 16:48:29 UTC 2022
PRIMARY RxNorm
IUPHAR
2881
Created by admin on Fri Dec 16 16:48:28 UTC 2022 , Edited by admin on Fri Dec 16 16:48:28 UTC 2022
PRIMARY
WIKIPEDIA
LEVONORGESTREL
Created by admin on Fri Dec 16 16:48:29 UTC 2022 , Edited by admin on Fri Dec 16 16:48:29 UTC 2022
PRIMARY
NCI_THESAURUS
C47585
Created by admin on Fri Dec 16 16:48:28 UTC 2022 , Edited by admin on Fri Dec 16 16:48:28 UTC 2022
PRIMARY
Related Record Type Details
Structure of DEXTRONORGESTREL
ENANTIOMER -> ENANTIOMER
Structure of NORGESTREL
RACEMATE -> ENANTIOMER
Related Record Type Details
Structure of 5.ALPHA.-DIHYDROLEVONORGESTREL
METABOLITE ACTIVE -> PARENT
Structure of 3.ALPHA.,5.BETA.-TETRAHYDRONORGESTREL
METABOLITE INACTIVE -> PARENT
PLASMA; URINE
NORELGESTROMIN
PARENT -> METABOLITE ACTIVE
Related Record Type Details
Structure of .DELTA.5(10)-LEVODIONE
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
Structure of 13?-Ethylgon-4-en-3,17-dione
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
Structure of 13-ETHYL-3-METHOXY-18,19-DINOR-17.ALPHA.-PREGNA-3,5-DIEN-20-YN-17-OL
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
Structure of 18-METHYL-19-NORTESTOSTERONE
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
Structure of 13-ETHYL-17-HYDROXY-18,19-DINOR-17.ALPHA.-PREGNA-5,7,9-TRIEN-20-YN-3-ONE
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
Structure of 13-ETHYL-17-HYDROXY-18,19-DINOR-17.ALPHA.-PREGN-5(10)-EN-20-YN-3-ONE
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
NORGESTIMATE
PARENT -> IMPURITY
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
Structure of NORETHINDRONE
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
Structure of 13-ETHYL-3-METHOXY-18,19-DINORPREGNA-2,5(10)-DIEN-20-YN-17-OL, (17.ALPHA.)-
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
Structure of METHOXYGONADIENE
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
Structure of .DELTA.5-LEVONORGESTREL
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
Structure of 13-ETHYL-17-HYDROXY-5.ALPHA.-METHOXY-18,19-DINOR-17.ALPHA.-PREGN-20-YN-3-ONE
IMPURITY -> PARENT
impurity O at 200 nm: maximum 0.3 per cent
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
Structure of 13-ETHYL-17-HYDROXY-18,19-DINOR-17.ALPHA.-PREGN-4-EN-20-YNE-3,6-DIONE
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
Structure of 13-ETHYL-3-METHOXY-18,19-DINOR-17.ALPHA.-PREGNA-1,3,5(10)-TRIEN-20-YN-17-OL
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
Structure of 13-ETHYL-3-METHOXYGONA-2,5(10)-DIEN-17.BETA.-OL
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
Structure of 10.BETA.-HYDROXYLEVONORGESTREL
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
Structure of 6.ALPHA.-HYDROXYLEVONORGESTREL
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
Structure of 13-ETHYL-18,19-DINOR-17.ALPHA.-PREGN-4-EN-20-YN-17-OL
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
Structure of .DELTA.6-LEVONORGESTREL
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
Structure of 6.BETA.-HYDROXYLEVONORGESTREL
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
Structure of 13-ETHYL-3-ETHYNYL-18,19-DINOR-17.ALPHA.-PREGNA-3,5-DIEN-20-YN-17-OL
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
Structure of 13-ETHYL-17-HYDROXY-18,19-DINORPREGNA-4,8(14)-DIEN-20-YN-3-ONE, (17.ALPHA.)-
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
Related Record Type Details
Structure of LEVONORGESTREL
ACTIVE MOIETY
NIH
NCATS
PRIVACY ACT
ACCESSIBILITY
DISCLAIMER
HHS VULNERABILITY DISCLOSURE
For language access assistance, contact the NCATS Public Information Officer
National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966